February 24, 2020
A full transcript of STARS-ADHD — the pivotal trial of Akili Interactive’s video game-like pediatric attention deficit treatment — has been published in The Lancet Digital Health journal, providing onlookers a clear view of data fueling the digital therapeutic company’s pending FDA submission.
The writeup echoes topline findings first unveiled by the company in December 2017: compared to a...
January 15, 2020
Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error.
Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication.
Called the ...
November 14, 2019
A personalized, interactive brain-training game will soon be helping children with Attention Deficit Hyperactivity Disorder (ADHD) improve their attention span. The advantage of this technology is that that children with ADHD can participate in this program from home. A pilot run for the home-based program will be launched for 20 children, aged 6-12 years, who are currently receiving treatment...
August 20, 2019
ATENTIV, maker of a video game-based intervention for ADHD, has partnered with Children’s Specialized Hospital’s Center for Discovery, Innovation and Development (CDID) to explore a novel care model blending both behavioral and primary care.
Of particular note, ATENTIV and CDID, part of the RWJBarnabas Health system in New Jersey, will be investigating how to deploy the therapy, called...
March 7, 2019
Boston-based Akili Interactive Labs, maker of video game-like treatments for children with ADHD and autism spectrum disorder, has found a partner to help promote its digital therapeutic products in eastern Asia.
Thanks to a new strategic partnership announced this morning, Osaka, Japan-based pharmaceutical company Shionogi will take over the commercialization, marketing, clinical development and...
January 3, 2019
A small feasibility study conducted by the Children’s Hospital of Philadelphia suggests that Project: Evo, the digital medicine developed by Akili Interactive Labs that is delivered via a video game, continually engaged children with autism spectrum disorder (ASD) and reduced their ADHD symptoms, although more objective measures of cognitive control were mixed.
Nineteen children aged...
August 20, 2018
A recent small study published in Nature’s Translational Psychiatry journal observed a change in the brain networking and behavior of boys receiving a video game-based treatment for ADHD.
Conducted in Singapore, the study was conducted as part of a larger controlled investigation of boys with ADHD. It compared an intervention group of 18 participants (mean age 9 years) to a control arm of 11...
December 4, 2017
Boston-based Akili Interactive Labs has announced positive results from the largest clinical trial of its video game-based pediatric ADHD treatment yet. In light of these data, the company announced that it now plans to file AKL-T01, also known as Project: Evo ADHD Treatment, for FDA clearance as a novel treatment for children and adolescents with ADHD
“This is, any way you slice it, our largest...
September 15, 2017
A brain-training video game shows promising signs for the treatment of ADHD in a new randomized clinical trial.
In the game, from developer NeuroPlus, children wear an EEG monitor and additional sensors that measure movement and muscle tension. The readings from those sensors actually control the game — in one game, the player rides a dragon that speeds up the more they focus and slows down when...
March 6, 2017
Japanese digital health company Welby has collaborated with Janssen, a pharmaceutical division of Johnson & Johnson, to develop a mobile app for people with attention deficit hyperactivity disorder, or ADHD. The app will be available on iOS and Android throughout Japan.
Aozora, the task management app, was created by Welby and will be distributed by Janssen to people with ADHD who are...